Senaparib and Bevacizumab for first-line maintenance in ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (Senaparib and Bevacizumab) as a first treatment after chemotherapy for women with advanced ovarian cancer that has a specific genetic feature called HRP. The goal is to see if this combination can help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that is stage III or IV.
- Your tumor is HRP (homologous recombination proficient), meaning it has a certain DNA repair profile.
- You have completed platinum-based chemotherapy and your cancer has either completely or partially responded (no growth).
- You have good organ function (kidney, liver, bone marrow) and are able to take oral medication.
- You have not used PARP inhibitors before and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two PARP inhibitors (drugs that help repair DNA damage) combined with bevacizumab (an anti-angiogenic therapy) as maintenance treatment after chemotherapy in patients with advanced ovarian cancer that has a genetic vulnerability called HRD-positive. The goal is to see which combination works better at preventing cancer recurrence.
This trial tests whether a maintenance treatment with fluzoparib (a PARP inhibitor) plus bevacizumab can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation and whose cancer responded to initial chemotherapy.
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
This trial tests whether adding olaparib, pembrolizumab, and bevacizumab as ongoing (“maintenance”) treatment can help control platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer that has responded to prior chemotherapy. It focuses on people whose tumors do NOT have BRCA1/2 gene mutations.
This trial tests a combination of two oral drugs (fluzoparib and apatinib) as maintenance therapy after chemotherapy for women with relapsed ovarian cancer. It might help keep the cancer from coming back for those who have already responded well to platinum-based chemo.
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Hear when a new Advanced Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.